Mapping the genetic changes in MPN
‘Atypical myeloproliferative neoplasms’ is the name given to a group of blood cancers that are rare and difficult to treat. Professor Nick Cross wants to understand more about how these diseases develop in the hope of finding new ways to treat them.
Atypical myeloproliferative neoplasms (aMPNs) are a group of rare blood cancers that are currently difficult to treat and haven’t been studied very much due to the rarity of these conditions. It’s very hard for doctors to predict how aMPNs will behave in terms of progression and response to treatment. They also generally have a poor outlook and current treatments often don’t work that well.
Professor Nick Cross and his team want to understand which genetic changes might be responsible for the development of the diseases that fall under the aMPN category and will study how these errors might be able to be targeted by treatments. They are also looking at whether certain genes that make people more likely to have one of these diseases could be passed on to children.
If successful, this research should improve our knowledge about the genes involved in this rare group of diseases, which will help improve how we diagnose and treat aMPNs.